CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Cantor Fitzgerald issued their FY2023 earnings per share estimates for CRISPR Therapeutics in a report released on Tuesday, October 17th. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will post earnings per share of ($2.36) for the year. Cantor Fitzgerald has a “Neutral” rating on the […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Cantor Fitzgerald issued their FY2023 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors on Tuesday, October 17th. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will post earnings per share of ($2.36) for the year. Cantor Fitzgerald has a “Neutral” […]
EFG Asset Management North America Corp. trimmed its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 21.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,985 shares of the company’s stock after selling 20,129 shares during the period. […]
Ipswich Investment Management Co. Inc. reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 1.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,585 shares of the company’s stock after selling 440 shares during […]